Immunovia’s Model Development Study Published in Cancers
9 juni, 09:00
A model development study from Immunovia (IMMNOV: Nasdaq Stockholm), the company focused on early detection of pancreatic cancer, has been published in the peer-reviewed journal Cancers. The publication marks an important validation of the company's technology and strengthens its position in early detection.
Using machine learning, the team identified a five-marker panel that showed 85% sensitivity at 98% specificity in detecting early-stage pancreatic cancer from high-risk controls. These results were previously shared, and the publication now provides independent, peer-reviewed validation of the findings. It further supports the test’s commercial and clinical viability in a high-need area.
"This publication in Cancers marks an important milestone for Immunovia as well as validation of PancreaSure, our new test which we will launch in September”, said Jeff Borcherding, Immunovia CEO. ”Peer-reviewed publication establishes the scientific rigor of our work and its potential impact on cancer care. We are grateful for our collaborators at Proteomedix, and scientific advisory board members who made this breakthrough possible.”
Read the article here: https://www.mdpi.com/2072-6694/17/11/1866
For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.
Attachments
Immunovia’s Model Development Study Published in Cancers
Ämnen i artikeln
Immunovia’s Model Development Study Published in Cancers
9 juni, 09:00
A model development study from Immunovia (IMMNOV: Nasdaq Stockholm), the company focused on early detection of pancreatic cancer, has been published in the peer-reviewed journal Cancers. The publication marks an important validation of the company's technology and strengthens its position in early detection.
Using machine learning, the team identified a five-marker panel that showed 85% sensitivity at 98% specificity in detecting early-stage pancreatic cancer from high-risk controls. These results were previously shared, and the publication now provides independent, peer-reviewed validation of the findings. It further supports the test’s commercial and clinical viability in a high-need area.
"This publication in Cancers marks an important milestone for Immunovia as well as validation of PancreaSure, our new test which we will launch in September”, said Jeff Borcherding, Immunovia CEO. ”Peer-reviewed publication establishes the scientific rigor of our work and its potential impact on cancer care. We are grateful for our collaborators at Proteomedix, and scientific advisory board members who made this breakthrough possible.”
Read the article here: https://www.mdpi.com/2072-6694/17/11/1866
For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.
Attachments
Immunovia’s Model Development Study Published in Cancers
Ämnen i artikeln
Investmentbolagen
-160x160.png&w=3840&q=75)
-160x160.jpg&w=3840&q=75)
Aktieråd
-992x558.jpg&w=3840&q=75)
VD-sortin i Rusta
Investmentbolagen
Aktieråd
VD-sortin i Rusta
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
